Tag Archives: media

Biochemistry

Top Diet and Nutrition Issues to be Highlighted during Jan. 29 Media-only Event – Newswise

MEDIA CONTACT

Available for logged-in reporters only

Newswise Nebraska food scientists are at the forefront in some of the hottest food and nutrition issues in the country the microbiome, which some predict to be one of the top nutrition issues in 2020; obesity, which continues to be a major health issue for the nation; food allergens, with the CDC reporting rising prevalence of food alelrgies in children; and food choice behavior.

On Jan. 29, a dozen researchers and scientists will be at the Food Innovation Center (1901 N. 21stSt., Lincoln, Nebraska) at Nebraska Innovation Campus to discuss their groundbreaking work with the media. The event begins at 11 a.m. with a brief overview of each research program. After a provided box lunch, media in attendance will have six 15-minute sessions to interview researchers. At 2 p.m., optional laboratory tours will be available for photos and b-roll. The event will be live-streamed for media who cannot attend in person.

Participating laboratories:

Nebraska Food for Health Center,Andy Benson, director, professor of food science and technology; Amanda Ramer-Tait, associate professor of food science and technology; and Robert Hutkins, Khem Shahani Professor of Food Science and Technology. The center is located in the Food Innovation Center, 1901 N. 21stSt., on the Nebraska Innovation Campus of the University of Nebraska-Lincoln.https://foodforhealth.unl.edu

Nebraska Center for Prevention of Obesity Diseases,Janos Zempleni, director, Cather Professor of Nutrition and Health Sciences; Jiujiu Yu, assistant professor of nutrition and health sciences; Xinghui Sun, assistant professor of biochemistry; Yongjun Wang, research assistant professor of nutrition and health sciences; Edward Harris, associate professor of biochemistry; Alice Ngu, graduate research assistant in nutrition and health sciences. The center is located at 316C Leverton Hall, 1700 N. 35thSt., on the University of Nebraska-Lincoln East Campus.https://cehs.unl.edu/npod

Food Allergy Research and Resource Program,Joseph Baumert, director, associate professor of food science and technology; Melanie Downs, assistant professor of food science and technology; Philip Johnson, assistant professor of food science and technology; and Richard E. Rick Goodman, research professor of food science and technology. The program is located in the Food Innovation Center, 1901 N. 21stSt. on the Nebraska Innovation Campus of the University of Nebraska-Lincoln.https://farrp.unl.edu

Food Choice Economics,Christopher Gustafson, associate professor of agricultural economics, 314A Filley Hall, 1625 Arbor Drive on the University of Nebraska-Lincoln East Campus.

The Food for Health Center, a $40.3 million collaboration among academics, food and drug manufacturers and philanthropists, was established in 2017 to use microbiome research to link agriculture and food production to wellness and disease prevention.

Launched in 2014, the Nebraska Center for the Prevention of Obesity Diseases has received nearly $23 million from the National Institutes of Health to determine the molecular mechanisms that lead to obesity and to identify consumer friendly remedies.

For nearly 25 years, the Food Allergy Research and Resource Program has worked in partnership with the food industry to detect and eliminate allergens in the food supply.

Behavioral economist Christopher Gustafson is identifying the hidden factors that cause people to add an extra dollop of mayo to their sandwich or select an apple, not a brownie for a post-workout snack.

Please contact Leslie Reed at 402-472-2059 orlreed5@unl.eduto reserve your space, including lunch, parking and optional lab tours.

More:
Top Diet and Nutrition Issues to be Highlighted during Jan. 29 Media-only Event - Newswise

Human Behavior

EDITORIAL: Be on the lookout for trolls of all stripes – Tahlequah Daily Press

When people used to think of "trolls," images of stout but ugly creatures, loitering under bridges waiting for goats or humans to cross, came to mind. But those are presumably fictitious characters, whereas modern "trolls" are all too real.

Folks who manage social media sites dedicated to news can tell you all about trolls, because their infestations give the fleas on a garbage-raiding raccoon a run for its money. They're not hard to spot. During posts that invite community discussions, such as TDP's Saturday Forum, they're the ones who make the most vicious comments, attacking the newspaper and respondents who don't share their views.

Trolls usually have no mutual friends with any other participants or anyone who works at the media outlet in question; in fact, they often have just one or two friends. They could have their friends lists hidden, but that's not the case if a few names can be seen. Trolls aren't always fake; some are all too real. But the most of these are almost never from the county where the media entity is based. This means they have no stake in the community, and would rather stir up trouble than engage in rational discussions.

Although the number of registered Republicans is growing, Cherokee County has long been a conservative Democratic area that votes blue locally and red at the national level. These days, more residents are eschewing the two major parties and registering Libertarian or independent, especially since they can vote in Democratic primaries. But with a few notable exceptions, even the most rabid Trump supporters or detractors in this area are generally civil to one another, though they may be passionate in expressing their views.

Trolls, either actual people or those masquerading under false identities, don't represent the demographics of the areas where they lurk, but they tend to infect social media sites operated by the "real" media. It's one reason why some readers and viewers feel uncomfortable making comments; they don't want to be attacked and demeaned for putting in their two cents' worth. Their reticence has prompted many media companies to begin pulling their punches and retreating to safe harbors.

Incidentally, social media commenters who attack newspapers for telling an uncomfortable truth have rarely ever subscribed to a paper, nor would they -- or they're mad because the publication reported something they or a family member did to embarrass themselves. In the latter case, the goal is retribution; in the former, the goal is to make anyone riding the fence, or anyone already on their side, believe they have a lot more support than they really do. These days, it's more about validation than persuasion. This is very effective against people who are vulnerable or too busy to do the research.

Real people who can defend their convictions use their own names, can be verified as actual people, and have friends in common with at least someone on a given thread. But not all unruly cretins are posers; the public should never underestimate support for, or opposition to, candidates when it comes to modern politics - even if those candidates seem repugnant. Experienced observers of human behavior know there are "sheep" on both sides, who will follow their idols no matter what.

Be on the lookout for trolls and trouble-makers, from wherever they come - and don't rise to the bait.

See more here:
EDITORIAL: Be on the lookout for trolls of all stripes - Tahlequah Daily Press

Cell Biology

Special delivery: McMaster physicists design super-human red blood cells to deliver drugs to specific targets within the body – Newswise

MEDIA CONTACT

Available for logged-in reporters only

Newswise A team of physicists from McMaster University has developed a process to modify red blood cells so they can be used to distribute drugs throughout the body, which could specifically target infections or treat catastrophic diseases such as cancer or Alzheimers.

The modified red blood cells are designed to circulate in the body for several weeks at a time, seeking out specific targets including bacteria, tumours or organs.

The technology, described in the online edition of the journal Advanced Biosystems, solves a major problem with current drug delivery methods that use synthetic molecules and cannot reach specific targets or are rejected by the body.

We call these super-human red blood cells. We think that they could work as the perfect stealth drug carriers which can outsmart our immune system, explains Maikel Rheinstdter, a senior advisor on the study and professor in the Department of Physics & Astronomy at McMaster.

The researchers have developed a method to open up the red blood cell, modify its outer cell wall, and replace its contents with a drug molecule, which would then be injected back into the body.

The hybrid appears and behaves as a normal red blood cell, but has a sticky surface which can attach itself to bacteria, for example, open up and release antibiotics exactly where they are needed.

We have combined synthetic material with biological material and created a new structure, which has never been done before in this way, says Sebastian Himbert, lead author and a graduate student in the Department of Physics & Astronomy at McMaster.

The entire process is very efficient and can be completed in one day in the lab, he says.

Researchers believe this targeted delivery method could help to minimize dosages and therefore, potential side effects. This is particularly important for very potent drugs used in cancer and Alzheimers disease, and the treatment of infections of potentially resistant bacteria.

The work was done in collaboration with Harald Stver, professor in the Department of Chemistry and Chemical Biology at McMaster, Janos Juhasz from the Juravinski Cancer Centre, and researchers at Saarland University in Germany.

A high res photo and video of researchers Maikel Rheinstdter and Sebastien Himbert can be found at this link: https://assets.adobe.com/public/907bc03f-19a0-4454-6dda-d1d10a57eb0a

Attention editors: A copy of the study can be found at the link below:

Adv. Biosys.2020, 1900185 Hybrid erythrocyte liposomes: functionalized red blood cell membranes for molecule encapsulation, Sebastian Himbert, Matthew J. Blacker, Alexander Kihm, Quinn Pauli, Adree Khondker, Kevin Yang, Sheilan Sinjari, Mitchell Johnson, Janos Juhasz, Christian Wagner, Harald D. H. Stver and Maikel C. Rheinstdter

Adv. Biosys.2020, 1900185

https://doi.org/10.1002/adbi.201900185

SEE ORIGINAL STUDY

Go here to see the original:
Special delivery: McMaster physicists design super-human red blood cells to deliver drugs to specific targets within the body - Newswise

Human Behavior

Global Web Analytics Market 2020-2024 | 19% CAGR Projection Over the Next Five Years | Technavio – Business Wire

LONDON--(BUSINESS WIRE)--The web analytics market size is poised to grow at a CAGR of over 19% during the period 2020-2024, according to the latest market research report by Technavio. Request a free sample report

The e-commerce industry is constantly evolving with the advent of new technologies and services. In addition, vendors are engaging in advanced marketing tactics to gain popularity and attract more customers. Consumer demand for personalized experiences, good services, and easy access to product information is also on the rise. Thus, enterprises that operate through e-commerce platforms analyze data collected from the websites to enhance website performance. The integration of web analytics helps online retailers to better understand consumer preferences by collecting information about website visitors so as to offer the right product offerings. Thus, the rising preference for online shopping will drive the web analytics market growth during the forecast period.

To learn more about the global trends impacting the future of market research, download free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40349

As per Technavio, the proliferation of AI in web analytics will have a positive impact on the market and contribute to its growth significantly over the forecast period. This research report also analyzes other important trends and market drivers that will affect market growth over 2020-2024.

Web Analytics Market: Proliferation of AI in Web Analytics

Vendors in the market are increasingly integrating artificial intelligence (AI) into web analytics, which can provide more processed information from websites and makes web analytics more convenient for online marketers and website holders. Furthermore, machine learning helps in studying the patterns of human behavior on websites and can be correlated and analyzed with web analytics tools to find the desired result. Thus, the benefits of integrating AI into web analytics will prompt enterprises to adopt web analytics during the forecast period.

Other factors such as the growing need for predictive analytics, and the increasing adoption of the cloud will have a significant impact on the growth of the web analytics market value during the forecast period, says a senior analyst at Technavio.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Web Analytics Market: Segmentation Analysis

This market research report segments the web analytics market by deployment (cloud-based and on-premises) and geography (APAC, North America, Europe, South America, and MEA).

The North American region led the market in 2019, followed by Europe, APAC, South America, and MEA respectively. The growth of the web analytics market share in North America can be attributed to factors such as the rising adoption of cloud computing services and the presence of various leading vendors in the region.

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.

Request a free sample report

Some of the key topics covered in the report include:

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation

Geographical Segmentation

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Link:
Global Web Analytics Market 2020-2024 | 19% CAGR Projection Over the Next Five Years | Technavio - Business Wire

Anatomy

The anatomy of a thriller: How the Nuggets sealed their clutch win over the Mavs – The Denver Post

DALLAS It was impossible not to feel sympathetic for Nikola Jokic as he wrestled with a weight in the hallway late Wednesday night considering what hed already accomplished.

As has become customary, Jokic, along with Juancho Hernangomez, Malik Beasley and the Nuggets strength trainers, grunted through a postgame workout that left Denvers superstar dripping in sweat when he finally met with the media following his game-winning bucket against the Mavericks.

Its always nice, Jokic said with a grin. Thats my after-game squad.

Less than half an hour earlier, Jokic was busy dominating Dallas frontcourt, bludgeoning them for 33 points, including 26 in the second half. He even buried four 3-pointers his ace in the hole, as he called his long-range weapon.

Though plenty happened throughout the first 47:52 at American Airlines Center, it was the final two possessions that sealed Denvers riveting 107-106 win. The victory was even more impressive considering the Nuggets were at the end of a taxing, 10-day road trip and without starters Paul Millsap and Will Barton.

Neither factor entered the players minds with Denver trailing 106-105 with 23 seconds left and the ball out of bounds on the sidelines.

Jamal Murray initiated the action with a tree-trunk screen on Mavericks center Dwight Powell to free up Jokic and force undersized forward Dorian Finney-Smith onto the Nuggets star. The only problem was that Jokic, who generally sees the game three steps ahead of his opponent, didnt recognize he had the mismatch.

Thats why I passed out, then I figured out that I had a mismatch, Jokic said.

That miscalculation nearly ended in disaster after Jokics pass to Murray was deflected and sent careening toward halfcourt.

Just track down the ball, Murray said laughing. He threw the ball, it went off me, so I had to go get it.

From there, Murray sent the ball back inside, where Jokic was waiting to go to work.

What Im most happy about that last possession is that we stayed with it, Nuggets coach Michael Malone said. We were able to get the re-post, he took his time and scored against a smaller guy in the post. So, hes our go-to player, hes an MVP candidate for a reason. And end of the games, the ball will be in his hands to make the right play.

But the work wasnt done after Jokic dropped his right shoulder, spun and laid in his 12th bucket of the night. There were eight seconds left, and the Mavericks still had one of the most lethal playmakers in the NBA at their disposal in Luka Doncic.

Its two of the most promising young players in the entire NBA, two of the best players in the world, Malone said of the two international stars. One guy from Slovenia, one guy from Serbia, and tonight on national TV, they put all their talents on full display. Im a coach, but Im also a huge fan of the game, I love the game of basketball. I love seeing great players play.

The Mavericks took a full timeout, and the Nuggets made their defensive adjustments. Out came their two offensive stalwarts, Jokic and Murray, in came versatile defenders Torrey Craig and Mason Plumlee. Together, along with rangy forward Jerami Grant, Gary Harris and Beasley, the Nuggets suffocated Dallas final attempt.

That last play, me and (assistant) Wes (Unseld Jr.) talked, Malone said. He said, You know if you want to hit (Luka), get the ball out of his hands. I said, You tell me. And he said, Lets do it.

The Nuggets first victory on the defensive highlight came via Grant not allowing Doncic to catch the inbounds pass, costing the Mavericks several precious seconds. After Doncic finally gained possession the Nuggets swarmed him, just as their coaches had asked.

Craig and Grant trapped him, forcing an outlet to the corner, which Beasley snuffed out almost immediately. From there, with the clock winding down, Plumlee flew in to block the baseline and extinguish any window for the Mavs to shoot. With nowhere to go, Finney-Smith threw the ball into the backcourt as time expired and the entire Nuggets bench charged onto the court.

We committed to it and our guys flew around behind him and we wound up forcing a turnover to seal the win, Malone said, beaming at his teams effort.

It was a shootout, Murray said. It was our defense that won the game.

Excerpt from:
The anatomy of a thriller: How the Nuggets sealed their clutch win over the Mavs - The Denver Post

Immunology

DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with…

Montrouge, France, January 8, 2020

DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy

Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment

Low discontinuations due to adverse events observed

Study represents the largest long-term peanut allergy immunotherapy trial to date, with high compliance enabling extended study participation

DBV Technologies (the Company) (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive topline results of the three-year, open-label extension of the Phase III PEPITES trial (PEOPLE) evaluating the long-term efficacy and safety of investigational Viaskin Peanut in peanut-allergic children ages 4 to 11 years. The results demonstrate long-term clinical benefit as shown by an increase in eliciting dose (ED), which may decrease the chance of reacting to an accidental peanut exposure. After three years, 75.9% (107/141) of patients had increased their ED from baseline, and 51.8% (73/141) of patients reached an ED of at least 1,000 mg peanut protein by year three.

These new long-term data support the overall clinical benefit of Viaskin Peanut that weve observed to date in Phase II and III clinical trials. We are particularly pleased to see that approximately three out of four patients showed an increase in their eliciting dose over three years, regardless of their individual baseline, with roughly 1 in 7 patients able to consume 5,444 mg peanut protein without reacting during the Month 36 oral food challenge, said Dr. David Fleischer, Principal Investigator of PEPITES and PEOPLE, Director, Allergy and Immunology Center and Section Head, Childrens Hospital Colorado. Most peanut-allergic children react to a single peanut (300 mg of peanut protein) or less, with some reacting to as little as 1 mg, leading many children and families to experience constant fear of accidental exposure, loss of normalcy and decreased quality of life. These new data provide further evidence that Viaskin Peanut may reduce the risk of reaction from accidental exposure by increasing threshold reactivity through a treatment option that could be safe and convenient.

The PEOPLE study is an ongoing open-label extension study evaluating the long-term safety, tolerability and efficacy of Viaskin Peanut 250 g in patients who have completed the Phase III PEPITES trial. Of the 213 patients who were randomized in the active treatment arm of PEPITES and completed the 12-month trial, 198 patients opted to enter the PEOPLE study (safety population). Of these patients, 148 were considered completers after 36 months and 141 patients completed all treatment according to the study protocol without major deviations. Efficacy data were analyzed from these 141 patients (per-protocol).

Topline results from PEOPLE support the long-term tolerability and clinical benefit of Viaskin Peanut, demonstrating desensitization over 36 months of treatment. After 36 months, 51.8% (73/141) of patients reached an ED of at least 1,000 mg peanut protein, an increase relative to Month 12, 40.4% (57/141). In addition, 13.5% (19/141) of patients completed the food challenge without meeting stopping criteria at 36 months (cumulative dose of 5,444 mg). At Month 36, the mean cumulative reactive dose (CRD) was 1,768.8 mg (median 944 mg) compared to 223.8 mg (median 144 mg) at baseline.

The safety profile of Viaskin Peanut was consistent with that observed in the clinical program to date in over 1,000 patients. During PEOPLE, the most common adverse events were mild to moderate skin reactions localized to the administration site and there was no epinephrine use deemed related to treatment. No treatment related serious adverse events (SAEs) were reported. One patient experienced one case of mild anaphylaxis that was determined by the investigator to be possibly related to treatment and resolved without treatment. Treatment compliance remained high throughout the study at a mean of 98% over three years of treatment.

Exploratory analyses suggest Viaskin Peanut may offer sustained effect even after a period without treatment. All participants who reached an ED 1,000 mg at Month 36 were eligible to continue the study for two additional months without treatment while maintaining a peanut-free diet. A further double-blind placebo-controlled food challenge to determine ED was administered at the end of this period (Month 38). The analysis showed that 77.8% (14/18) of the children who completed the oral food challenge at Month 38 maintained desensitization with an ED 1,000 mg.

Harnessing the important immune properties of the skin, epicutaneous immunotherapy represents a potentially unique mechanism of action that may support the sustained desensitization observed in this study even after a period without treatment. These data further advance our understanding of the profile of Viaskin Peanut, which is currently under review by the U.S. Food and Drug Administration and may offer a simple, once daily, non-invasive treatment option for children living with peanut allergy in the second half of 2020, if approved, said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies. Importantly, we would like to thank the children, families and investigators for participating in this study, the largest long-term trial in this underserved disease.

The Company plans to present full study results at future medical congresses as well as submit for publication in a peer-reviewed journal.

About PEOPLEThe PEOPLE study is an open-label extension of the Phase III PEPITES trial designed to evaluate the long-term safety, tolerability and efficacy of Viaskin Peanut 250 g (NCT03013517). Participants who completed the 12-month study period of PEPITES were eligible to enroll in PEOPLE. Patients who were randomized to active treatment in PEPITES are eligible to receive up to four additional years of treatment, and those previously receiving placebo are eligible to receive up to five years of treatment.

The study evaluates the eliciting dose after three years (Month 36) of active treatment using a double-blind, placebo-controlled food challenge (DBPCFC). The starting dose of each challenge is 1 mg of peanut protein and escalates to the highest dose of 2,000 mg peanut protein; possibly repeated once to reach a maximum total cumulative dose of 5,444 mg peanut protein. For the next DBPCFCs after four and five years, the starting dose of each challenge is 10 mg of peanut protein and escalates to the highest dose of 3,000 mg peanut protein; possibly repeated once to reach a maximum total cumulative dose of 6,440 mg peanut protein.

The analysis also includes exploratory assessments of safety parameters, immune biomarkers such as immunoglobulin E (IgE) and immunoglobulin G4 (IgG4), and sustained desensitization following a two-month period without treatment.

About PEPITESThePeanutEPIT Efficacy andSafety Study (PEPITES) was a global, double-blind, placebo-controlled Phase III trial designed to evaluate the safety and efficacy of Viaskin Peanut 250 g in children ages 4 to 11 years (NCT02636699). PEPITES was conducted in 31 centers across North America (Canada and the United States), Germany, Ireland and Australia.

Eligible patients were aged 4-11 years at screening with physician-diagnosed peanut allergy, currently following a strict peanut-free diet. Other key inclusion criteria were peanut-specific IgE >0.7 kUA/L, a peanut skin prick test with a largest wheal diameter 6 mm (children 4-5 years) or 8 mm (children 6 years) at screening, and an ED (the single highest dose at which a patient exhibited objective signs/symptoms of an immediate hypersensitivity reaction) of 300 mg peanut protein based on a DBPCFC.

PRACTALL,the joint American Academy of Allergy, Asthma & Immunology (AAAAI) and European Academy of Allergy and Clinical Immunology (EAACI) published food challenge methodology that defines strict, 30-minute intervals for peanut protein dosing, was used to evaluate sensitivity to peanut at baseline and exit.Challenges were stopped when patients exhibited clear, objective symptoms based on a pre-specified symptom scoring scale. A Good Manufacturing Practice food challenge matrix was used for all peanut protein and placebo food challenges.

During PEPITES, patients responses were assessed using DBPCFCs. Patients were randomized 2:1 to receive either Viaskin Peanut 250 g or placebo for 12 months. The primary endpoint was based on a responder analysis after 12 months of treatment with Viaskin Peanut 250 g. For patients with a baseline peanut protein ED equal to or less than 10 mg, a responder was defined as a patient with a peanut protein ED equal to or greater than 300 mg of peanut protein after 12 months of treatment. For patients with a baseline ED greater than 10 mg, a responder was defined as a patient with a peanut protein ED equal to or greater than 1,000 mg of peanut protein after 12 months of treatment.

As a secondary efficacy endpoint, CRD was also evaluated in PEPITES to establish the total quantity of peanut protein that triggers patient reactions at Month 12 of active treatment versus placebo. Serological markers were also measured at baseline, 3, 6, and 12 months in order to characterize the immunological changes in patients.

During the study, investigators relied on the commonly used National Institute of Allergy and Infectious Diseases (NIAID) definition of anaphylaxis, which has been shown to be highly sensitive but only moderately specific in diagnosing anaphylaxis, in an attempt to capture as many potential reactions as possible.

Two hundred thirteen of the 238 patients randomized to the peanut-patch and 107 of the 118 patients randomized to the placebo-patch completed the study. After 12 months of therapy, patients treated with Viaskin Peanut showed a statistically significant improvement in the ED of peanut required to provoke an allergic reaction at food challenge compared with placebo. After 12 months of treatment, we observed that 35.3% of patients on Viaskin Peanut 250 g were responders, compared to 13.6% of patients in the placebo group (treatment difference = 21.7%; 95% CI = 12.4% - 29.8%; p<0.001). An increase in the CRD was also observed between the treatment and placebo groups (nominal p-value<0.001) after 12 months. The median CRD of patients in the treatment group increased from 144 mg at baseline to 444 mg at Month 12, compared with no improvement in the placebo group.

There were no cases of severe anaphylaxis, and only four of 238 patients (1.7%) dropped out due to treatment-emergent adverse events. A low rate of treatment-related epinephrine use was reported (2.9% treatment group vs. 0.8% placebo group). Ten cases in eight Viaskin Peanut patients (3.4%) of possibly or probably treatment-related anaphylaxis occurred; all were classified as mild or moderate without evidence of cardiovascular, neurologic, or respiratory compromise. Six of these ten cases were treated with epinephrine, and five of the eight patients continued on Viaskin Peanut in the study.

About DBV TechnologiesDBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical trial of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Companys ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Companys ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Forward Looking StatementsThis press release contains forward-looking statements, including statements about the potential of the EPIT platform and Viaskin Peanut as a treatment for peanut-allergic children. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Factors that could cause actual results to differ materially from those described or projected herein include risk associated with uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals. A further list and description of these risks, uncertainties and other risks can be found in the Companys regulatory filings with the French Autorit des Marchs Financiers and U.S. Securities and Exchange Commission, including in the Companys Annual Report on Form 20-F for the year ended December 31, 2018. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise forward-looking statements as a result of new information, future events or circumstances, or otherwise, except as required by law.

DBV Investor Relations Contact Sara Blum ShermanSenior Director, Investor Relations & Strategy+1212-271-0740sara.sherman@dbv-technologies.com

DBV Media Contact Joe BeckerVP, Global Corporate Communications +1646-650-3912joseph.becker@dbv-technologies.com

Read more from the original source:
DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with...

Cell Biology

CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics -…

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Click to copy

NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The New York Stem Cell Foundation (NYSCF) Research Institute today announced a partnership with Cytovia Therapeutics Inc. (Cytovia) to develop new disease treatments that leverage human stem cell research and novel gene editing techniques. NYSCF will be a key partner to Cytovia in using stem cells to advance novel therapeutic targets for cancer.

Cytovia leverages NK cells to make these novel therapeutics more specific to cancer cells. NK or natural killer cells are immune cells that scan the body and attack infected or abnormal cells, often serving as a first line of defense against cancer. CAR (chimeric antigen receptor) NK cells are genetically engineered to better locate and attack tumors. CAR NK-based treatments are currently showing promise in clinical trials and could serve as a potent and cost-efficient alternative to current immunotherapies. Establishing high-quality, stem-cell-derived NKs and CAR NKs will help improve these treatments and accelerate their path to the clinic.

The NYSCF Research Institute is a pioneer and acknowledged leader in stem cell technology, having developed the NYSCF Global Stem Cell Array, the premier automated robotic platform for reprogramming adult cells into induced pluripotent stem cells (iPSCs). These iPSCs carry the genetic blueprint of the person from whom they are derived and can be turned into any cell type in the body, allowing scientists to study disease mechanisms in affected cells or modify them for use in therapeutics.

Our mission is to bring lifesaving treatments to patients around the world and we are excited to further this goal in partnership with Cytovia, says NYSCF CEO and founder Susan L. Solomon. It is critical that we collaborate with partners using our technology and expertise to bring innovative treatments to the market.

We are delighted to collaborate with the NYSCF Research Institute to develop iPSC-derived NK and CAR NK therapeutics, says Dr. Daniel Teper, CEO of Cytovia. By integrating NYSCFs world-class stem cell know-how and the precision gene-editing research conducted at the University of California San Francisco, Cytovia aims to become a leader in NK cell therapeutics for the treatment of cancer.

About The New York Stem Cell Foundation Research Institute The New York Stem Cell Foundation (NYSCF) Research Institute is an independent non-profit organization accelerating cures and better treatments for patients through stem cell research. The NYSCF global community includes over 190 researchers at leading institutions worldwide, including the NYSCF Druckenmiller Fellows, the NYSCF Robertson Investigators, the NYSCF Robertson Stem Cell Prize Recipients, and NYSCF Research Institute scientists and engineers. The NYSCF Research Institute is an acknowledged world leader in stem cell research and in the development of pioneering stem cell technologies, including the NYSCF Global Stem Cell Array, which is used to create cell lines for laboratories around the globe. In 2019, NYSCF launched its Womens Reproductive Cancers Initiative, which aims to shift paradigms in the way these cancers are studied and treated, in collaboration with leading cancer experts across the globe. NYSCF focuses on translational research in an accelerator model designed to overcome barriers that slow discovery and replace silos with collaboration. For more information, visit http://www.nyscf.org.

About Cytovia Therapeutics Inc. Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies. Learn more at cytoviatx.com

Contact information:CYTOVIA Therapeutics:Anna Baran-DjokovicVP, Corporate Affairs anna@cytoviatx.com

Cytovia Media Contact: Charlotte Tomic charlotte@tomiccommmunications.com Cell: 9178825243

NYSCF Research InstituteDavid McKeonChief of Staff dmckeon@nyscf.org

View post:
CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics -...

Human Behavior

Should Tesla Take The Initiative To Better Monitor And Manage Driver Behavior With Autopilot? – Forbes

A video call while a car is driven by an autopilot. Is there a need to couple driver monitoring with ... [+] collaborative automation?

By any account, Teslas Autopilot feature has come a long way since being released to consumers through an Over-The-Air (OTA) update just over 4 years ago. At inception, it was at best an incredibly sophisticated bootstrapped system based upon a Mobileye sensing platform and limited processing capabilities. With Teslas newer computing and data platforms, Autopilot is clearly one of the worlds more complex and impressive applications of a learning based Artificial Intelligence (AI) system.

The safety of Autopilot continues to be questioned by experts worldwide. A recent letter from Senator Markey to Elon Musk adds to an already heated conversation. In a post earlier this year on the Tesla automation strategy, I raised the question of whether it is appropriate for consumers to be used as test subjects, the need for a well validated measure of risk associated with the use of Autopilot, and the need for camera-based driver monitoring to manage inattention. In the months since, visuals in the media of drivers falling asleep, engrossed in non-driving activities, and otherwise participating in inattentive driving continue to appear. Seemly random, but realistically predictable, crashes keep happening that might be preventable with camera-based driver monitoring and driver management.

The reason crashes are predictable is that humans have long been known to be poor overseers of highly automated systems. When a supervisor feels that the automation is trustable, the irony is that there will be an increase in the number of system failures that are not mitigated correctly by a human supervisor. It simply becomes increasingly difficult to sustain attention as automation becomes more reliable. There is a painful history in transportation safety showing this. Recently, the National Transportation Safety Board (NTSB) detailed these types of failures in investigations of several Autopilot crashes and the tragic 2018 Uber fatality.

Perhaps paradoxically, it could be argued that with the explosive use of Autopilot, we would expect to see more crashes. However, the work from the late Raja Parasuraman and his students would suggest that imperfect automation (like Autopilot) keeps many users from becoming too complacent. In essence, its possible that the failure of a few individuals to appropriately oversee and collaborate with the automation is mixed with more responsible use by many.

This is not a new phenomenon for automotive engineers. It has long been known that it is difficult to engineer for all. Some drivers choose to speed, pick-up their phones, and be otherwise irresponsible with respect to other drivers with which they share the road. Are close-calls and crashes with Autopilot really more frequent than other cases of attention failures? Or are they just more easily associated with the evolution of a new and perhaps transformative (and perhaps over marketed) technology? Over the coming years there will likely be many efforts to better understand, and arguments around answering, these formidable questions. One clear difference from the introduction of previous generations of automotive systems is that todays social media driven society is helping to highlight problematic events.

The images and video that accompany todays social posts have increasingly brought what was once largely hidden from public view into the limelight. This naturally presses consumers, safety advocates, regulators and even politicians into a position of judging the social ethics of how technologies are implemented.

Given this new reality, Senator Markys letter to Mr. Musk questioning if Tesla is tracking or monitoring online videos to learn about inappropriate use of the Autopilot, is right on track. Something else to consider is that Tesla Model 3s are equipped with a cabin camera. Might Tesla use this sensor, and a fraction of their technological image processing prowess, to better gauge the state of drivers? Even a rudimentary driver monitoring system might be able to detect an outright inattentive driver asleep at the wheel or head down for seconds on end.

Manufacturers such as GM and BMW have introduced camera-based driver monitoring and management systems with the launch of their collaborative driving systems (i.e., SAE L2). One has to suspect other manufacturers will follow this seemingly reasonable route to market, bridging the time till automated systems that do not depend on attentive human back-up are truly available.

Just as outliers may be responsible for the majority of risky behavior associated with Autopilot, might Tesla be passively accepting undue risk compared to the rest of the market? Growing evidence suggests that Autopilot is placing drivers, and perhaps the automotive industry, in a precarious position. The aviation industry has long known that one airlines accident impacts trust in all airlines.

With a call to reinvent driving through the greater use of automation, is it time for the automotive industry to collaborate to increase the likelihood that the introduction and refinement of these technological approaches to making driving safer in the years ahead will have the greatest potential to succeed?

Following efforts in Europe, and using a framework similar to the NHTSA-IIHS collaborative industry agreement on AEB, could manufacturers and the government come together to take another step forward in safety by collaboratively agreeing to install camera-based driver monitoring systems to work alongside collaborative driving features?

Some might argue that a detailed, performance-based standard for systems is needed. However, starting with a fairly broad and open concept may be a more realistic starting point, and a Federal Motor Vehicle Safety Standard (FMVSS) could be more easily justified as experience is gained and the cost / benefit justification of a standard emerges. Working together to develop guardrails around the deployment and testing of automation on public roads might be the most important step to accelerate the adoption of potentially lifesaving automated vehicle technologies.

Originally posted here:
Should Tesla Take The Initiative To Better Monitor And Manage Driver Behavior With Autopilot? - Forbes